CJC-1295 + Ipamorelin

Blend of a GHRH analog and a selective ghrelin receptor agonist

Also sold as: CJC-1295 Ipamorelin blend · CJC/Ipa · CJC-1295 no DAC + Ipamorelin

The most common growth-hormone peptide pairing, sold as one vial containing two peptides — which means one shared volume and no way to adjust them separately.

Research chemicalResearch use only

What the evidence says

CJC-1295 + Ipamorelin is a blend or product code with no literature of its own. The evidence below belongs to its component compounds, not to this product.

CJC-1295

A synthetic growth-hormone-releasing hormone (GHRH) analog that raises GH and IGF-1 in humans, but has no proven clinical benefit and is sold only as a research chemical.

CPreliminaryRaises GH and IGF-1 secretionA measurable, dose-dependent biomarker effect shown in a small human study.
UUnknownFat loss / body-composition changeUnknown; no controlled human trials measured this.
UUnknownMuscle growth / lean massUnknown; no human outcome data.
EUnsupportedAnti-aging / recovery / sleepMarketed heavily, but unsupported by controlled evidence.
UUnknownLong-term safetyUnknown; no long-term human safety data exist.

Full CJC-1295 evidence profile →

Ipamorelin

A selective growth-hormone secretagogue that raises GH without spiking cortisol or prolactin — but its clinical benefits are unproven and it is sold only as a research chemical.

CPreliminaryRaises GH secretionA selective, measurable biomarker effect with limited human PK/PD data.
EUnsupportedPostoperative ileus (recovery of bowel function)Tested in a randomized trial and did not succeed; development was halted.
UUnknownFat loss / body-composition changeUnknown — no human outcome trials.
UUnknownMuscle growth / recovery / anti-agingUnknown — extrapolated from the GH effect, not demonstrated.
UUnknownLong-term safetyUnknown — no long-term human safety data exist.

Full Ipamorelin evidence profile →

This blend has no literature under its own name. The evidence shown above belongs to CJC-1295 and ipamorelin individually, and both sit at C for raising GH and U for every downstream outcome.

No controlled trial has tested the combination.

One vial means one ratio, permanently

The practical consequence of a blend is structural rather than pharmacological: two peptides share one powder and one reconstitution volume, so every draw pulls both in whatever ratio the manufacturer set. You cannot raise one and hold the other.

That is why a blend cannot be adjusted, and it is the reason the ratio on the certificate matters more than the total strength.

What a blend COA has to state

Per component: identity by mass spectrometry, and strength. A single purity percentage for the vial is compatible with almost any ratio, including one where the cheaper peptide dominates.

This is the most common gap in blend certificates, and it is the one that costs money.

Which CJC-1295?

The catalog lists this pairing alongside a standalone “CJC-1295 (No DAC)” product. With DAC and without are meaningfully different — the DAC modification extends the half-life substantially, which changes what a dosing schedule means.

Blend labels frequently omit it. The comparison covers what actually differs; the certificate is where you confirm which one you have.

Before you buy

The COA must state each component and each component's strength separately. A single purity figure for a blend tells you nothing about the ratio.

Confirm which CJC-1295 is in it — with DAC or without. They have very different half-lives and the label often omits it.

Require mass-spec identity for both peptides, not just the more expensive one.

Understand the ratio is fixed at manufacture. One draw pulls both proportionally; you cannot change one without changing the other.